Company Overview - Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities [2] - The company's products assist in scientific investigations into biological processes, disease progression, drug discovery, and accurate clinical tests and diagnoses [2] - Bio-Techne has a portfolio of hundreds of thousands of products and generated approximately $1.2 billion in net sales in fiscal 2024 [2] - The company employs approximately 3,100 people worldwide [2] Upcoming Event - Kim Kelderman, President and CEO of Bio-Techne, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 10:30 a.m. PST [1] - A live webcast of the presentation will be available on Bio-Techne's Investor Relations website [1]

Guangzhou, Dec. 19, 2024 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 Class A ordinary shares (the “Ordinary Shares”) at a public offering price of $4.00 per share for total gross proceeds of approximately $5,000,00 ...

MINNEAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex™ System) and liquid chromatography mass spectrometry (BioAccord™ LC-MS S ...

ST. PAUL, Minn., Dec. 18, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell therapy for the treatment of solid tumors."We are grateful to receive a G-Rex Grant to support the advancement of our lead CAR T asset into the clinic in a platform that ...

Bio-Techne Corp. (TECH) has launched a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer.The research-use-only assay, which includes a qPCR detection kit and an isolation kit for cell-free DNA and exosomal RNA, will also be featured at the ongoing San Antonio Breast Cancer Symposium. The latest development is expected to bolster the company’s Diagnostics and Spatial Biology segmen ...

Core Insights - Bio-Techne (TECH) is advancing in its four growth verticals, which are expected to drive growth in upcoming quarters [1] - The company has achieved ISO 13485 certification and is now pursuing clinical diagnostic opportunities on the Ella platform [1][6] - Acquisitions remain a key strategy for Bio-Techne to expand its portfolio and enter adjacent markets, despite facing macroeconomic challenges and competitive pressures [1][7][10] Growth Verticals - The Proteomics Analytical Instrumentation franchise, under the ProteinSimple brand, reported mid-single-digit growth in fiscal 2024, driven by SimplePlex and SimpleWestern products [4] - The Cell and Gene Therapy vertical is experiencing growth due to strong biotech funding and customer additions [4] - The Diagnostics and Spatial Biology vertical is showing solid growth, with positive responses from newly added RNAscope assays [5] - The Molecular Diagnostics vertical achieved nearly 40% growth in the first quarter of fiscal 2025, particularly in the ExoDx prostate test and Asuragen kit business [5] Ella Platform and Strategic Acquisitions - The Ella platform, following ISO 13485 certification, is gaining traction in clinical diagnostics, particularly for cell and gene therapy applications [6] - Bio-Techne's acquisition of Lunaphore is aimed at scaling up instrument production capacity to meet demand [7] - The company has made a 19.9% investment in Wilson Wolf and plans to acquire the remaining ownership by the end of calendar year 2027 [8] Challenges - The macroeconomic environment, especially in Asia Pacific and Europe, is leading to increased raw material and labor costs, which may impact operations through 2024 [10] - Bio-Techne faces intense competition from both large global companies and smaller niche players, leading to pricing pressures [11] Financial Performance - Over the past year, Bio-Techne's shares have increased by 15.4%, outperforming the industry growth of 0.9% [2] - The company's market capitalization stands at $11.97 billion, with fiscal 2025 earnings estimates recently adjusted down by 6 cents to $1.92 [2][12] - Revenue estimates for fiscal 2025 are projected at $1.22 billion, indicating a 5.6% increase from the previous year [12]

WEST SACRAMENTO, Calif., Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ: TECH).GeminiBio has a 39-year history of supporting FBS customers. With this agreement, GeminiBio builds ...

ST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation and CellReady, has awarded G-Rex Grants totaling $475,000 to three leading investigators at the Baylor College of Medicine's (BCM) Center for Cell and Gene Therapy Institute (CAGT). Dr. Ann Leen, a Professor in the Department of Pediatrics at BCM's CAGT, received a $275,000 G-Rex Grant for process development and IND enabling studies related to tumor-associated neoantigen spec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other ...

Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President and Chief Executive Officer Jim Hippel - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Jacob Johnson - Stephens Dan Leonard - UBS Thomas DeBourcy - Nephron Research Justin Bowers - Deutsche Bank Tom Peterson - Baird Matt Larew - William Blair Sung Ji Nam - Scotiabank Operator Goo ...